GL1X · GenesisL1 explorer

MolNFT v1 · #82937 · protein

Structure of aurora kinase a complexed to benzoimidazole-indazole inhibitor xv

3W2C: “Structure of aurora kinase a complexed to benzoimidazole-indazole inhibitor xv”. X-ray diffraction, 1 ligand (N15), 12 pockets (best druggability 0.77). MolNFT v1 #82937 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
3W2C
Type
protein
Length
809 residues
Chains
4
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Aurora kinase a
EC
2.7.11.1
UniProt
O14965
Ligands
N15
Pockets
12 · best druggability 0.77

Structure

x-ray diffraction · 2 distinct chains · 34% helix, 22% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AAurora kinase a (EC 2.7.11.1)protein20333% helix, 22% strandO14965
C, E, GAurora kinase a (EC 2.7.11.1)protein20235% helix, 23% strandO14965

Ligands and binding sites

  • N15 · 2-{4-[3-(1H-benzimidazol-2-yl)-1H-indazol-6-yl]-1H-pyrazol-1-yl}-N-(3-methylbutyl)acetamide · ligand · 4 copies · chains A, C, E, G

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

12 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110950.770.79111N15
24730.690.7957N15
33030.680.8239N15
41550.500.7818empty
51620.480.7723empty

Interfaces

2 interfaces between chains.

  • A–C · 389 Ų buried · 3 hydrogen bonds · protein-protein
  • E–G · 276 Ų buried · 1 hydrogen bond · protein-protein

Compared structures

  • 3W2C · Structure of Aurora kinase A complexed to benzoimidazole-indazole inhibitor XV · the same entry in another collection · chain E against E, TM-score 1.00
  • O14965 · AlphaFold monomer V2.0 prediction for aurora kinase a (O14965) · a predicted model of the same protein · chain E against A, TM-score 0.96

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.